Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

PM Images/DigitalVision via Getty ImagesThis is my third Outlook Therapeutics (NASDAQ:OTLK) article. As I will discuss, its situation is getting stickier in terms of current liquidity and timing. I am downgrading my Strong Buy rating from 06/2024's "Outlook Therapeutics: Worth A Good Strong Look After CRL"; instead, I am rating it a Buy. In doing so, I am emphasizing its risks. Outlook's Wet AMD therapy's massive blockbuster potential compared to its current puny market cap presents an unusual opportuni ...